JMP reiterates ViroPharma at market outperform

ViroPharma Inc. was reiterated at market outperform by JMP Securities analyst Adam Cutler on positive outcomes from the company's phase 2 study of maribavir for the prevention of cytomegalovirus infection in patients receiving bone marrow transplants. JMP expects ViroPharma to begin phase 3 studies for maribavir in bone marrow transplant patients around mid-year. Shares of the Exton, Pa., pharmaceutical company were up $1.10, or 9.41%, at $12.79 on volume of 18,635,626 shares versus the three-month running average of 3,504,290 shares. (Nasdaq: VPHM)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.